Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study.

Maria Elisa MancusoJohnny N MahlanguRobert SidonioPeter TraskMarianne UguenTiffany ChangMidori Shima Guy Aaron Young Johannes OldenburgSylvia von Mackensen

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Prophylactic emicizumab is accompanied by substantial and sustained improvements in HRQoL of paediatric PwHA with FVIII inhibitors and their caregivers.

Keyphrases

intensive care unit
emergency department
young adults
palliative care
risk factors